A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 366 participants.
Also called NCT02227784
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 366 participants
- Sponsor
- Registry
-
NCT02227784
-
- Other papers using this trial's data
- Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Terminated
Technical summary
Registry record NCT02227784. Randomized; double masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2018-03-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
- Acronym
- ACCENTUATE
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Evacetrapib
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02227784- Content hash
391f920180ed0e05fa7f246ea42fabb8ddebcb5bd0bf7844d8211b432c37fba5